ClinicalTrials.gov
public full text
Public Domain
Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder
This study will examine whether extended release galantamine, a drug approved by the Food and Drug Administration to reduce cognitive impairments in people with Alzheimer's disease, can perform the same function in stable people with bipolar disorder.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder#902814
- The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease#1124405
- A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment#805969
- A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease#857055
- Galantamine Effects on Cognitive Function in Abstinent Cocaine Users#1310610
Record · ID 1396859
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive